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The Hospital Infection Control Practices Advisory
Committee published guidelines for prudent use of van-
comycin to combat increasing resistance to antimicrobial
drugs. Studies examining compliance with these guidelines
primarily involve hospitalized patients. The growing prac-
tice of home use of antimicrobial drugs led to this retro-
spective cohort study that evaluated parenteral
vancomycin use in patients receiving it through a homecare
agency. We found that 39.2% of outpatients received van-
comycin outside the guidelines, mainly because of pro-
longed empiric therapy, dosing convenience, and
prolonged use after surgery. Patients were more likely to
receive vancomycin appropriately if they were >65 years of
age, had a history of malignancy, or were discharged from
a medical service. In addition, obtaining wound cultures
and attempting a microbiologic diagnosis led to more
appropriate vancomycin use. Recommendations for pru-
dent vancomycin use are often overlooked when selecting
antimicrobial drugs for home infusion. The public health
impact of this practice remains unknown.
V
ancomycin is an important agent for the treatment of
serious infections caused by gram-positive bacteria
(1). Over the past 3 decades, its use has steadily increased
because of increasing prevalence of β-lactam-resistant
nosocomial pathogens, particularly, methicillin-resistant
Staphylococcus aureus (MRSA) and coagulase-negative
staphylococci (CoNS) (2,3). A consequence of this
increased use has been the emergence and spread of van-
comycin-resistant enterococci, the isolation of S. aureus
with reduced susceptibility to glycopeptides, and, most
recently, reports of infections caused by vancomycin-
resistant S. aureus (4–6).
Antimicrobial stewardship guidelines have been devel-
oped to ensure that vancomycin is used appropriately and
retains its viability in the therapeutic armamentarium. The
most broadly accepted benchmark was published by the
Hospital Infection Control Practices Advisory Committee
(HICPAC) of the Centers for Disease Control and
Prevention (7). These guidelines and most efforts to con-
trol use of antimicrobial drugs target the hospital setting
(8–12). However, the prevalence of drug-resistant
pathogens in outpatient and ambulatory settings is increas-
ing, as demonstrated by the prevalence of penicillin-resist-
ant pneumococci and recent emergence of community-
onset MRSA (13,14). With an increasing number of
patients receiving home infusions of antimicrobial drugs,
the appropriateness of choices of drugs for outpatients
warrants scrutiny. Guidelines for the administration of out-
patient parenteral antibiotic therapy (OPAT) noted this and
encouraged adherence to HICPAC guidelines (15).
We conducted a retrospective cohort study of patients
discharged from an academic medical center to complete a
course of intravenous vancomycin at home. The main
objectives were to describe the epidemiology of outpa-
tients receiving vancomycin through a home healthcare
agency, determine the appropriateness of outpatient van-
comycin prescriptions according to HICPAC guidelines,
and examine factors associated with outpatient van-
comycin use that conformed to HICPAC guidelines.
Methods
Study Setting and Patient Population 
Northwestern Memorial Hospital (NMH) is a 725-bed
teaching hospital in Chicago, Illinois. Northwestern
Memorial Home Health Care, Inc. (NMHHC), the home
healthcare agency affiliated with NMH, receives >200
annual referrals for home infusion of antimicrobial agents. 
This study included all inpatients at NMH referred to
NMHHC to complete a course of intravenous vancomycin
therapy from December 1997 to April 2002. Patients were
excluded if they were <16 years of age, admitted to the
hospital already receiving vancomycin, discharged to any
other facility, or received care from another homecare
agency before referral to NMHHC. For patients with
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USAmultiple referrals to NMHHC for vancomycin therapy,
only their first treatment episode was included. During this
study, although vancomycin use guidelines were published
and distributed within NMH, no formal enforcement poli-
cy existed within the hospital or homecare setting. The
institutional review board of Northwestern University
reviewed and approved the study protocol.
Clinical Data
All data were originally collected as part of routine
patient care. For this study, clinical data were abstracted ret-
rospectively by review of existing inpatient medical
records, home health referral forms, and the inpatient phar-
macy database. The data abstractor had no part in the orig-
inal data collection. The following data were abstracted:
demographic information, length of hospital stay, admitting
service, insurance status, allergy to β-lactam antimicrobial
drugs, level of serum creatinine on the day of discharge,
history of end-stage renal disease requiring dialysis, infec-
tious diseases consultation, use of vancomycin in the hos-
pital, reason(s) for vancomycin use, and discharge
diagnoses per ICD-9 codes. ICD-9 codes were used to cal-
culate a mean Charlson comorbidity score for each patient
(16,17). With 1 exception, the presence of infectious syn-
dromes was determined by review of ICD-9 diagnoses. A
diagnosis of bloodstream infection was assigned if multiple
positive blood cultures were documented, regardless of
coded diagnoses. Because of the retrospective nature of the
evaluation, all recorded allergies to β-lactam antimicrobial
drugs were considered potentially serious.
Microbiologic Data
The microbiology records spanning the length of the
hospitalization for each patient were reviewed. A microbi-
ologic evaluation occurred if cultures were obtained that
reasonably corresponded to the infectious diagnosis
requiring the use of vancomycin. Record review focused
on collection of cultures from blood, other sterile sites,
urine, sputum, intravenous catheters or other foreign bod-
ies, and wounds or tissues. Bacterial isolates that were
specifically recorded were gram-positive organisms whose
treatment might prompt or warrant the use of vancomycin,
including methicillin-susceptible S. aureus, MRSA, CoNS,
streptococci, ampicillin-resistant or -susceptible entero-
cocci, and Corynebacterium jeikeium.
Evaluation of Vancomycin Use
HICPAC guidelines served as the basis for determining
whether patients received parenteral vancomycin per
guidelines or outside guidelines (Table 1). The guidelines
pertaining to prophylaxis for endocarditis (1C), surgical
procedures (1D and 2A), and low-birthweight infants (2G)
did not apply and were disregarded.
In addition, vancomycin use was determined to fall out-
side HICPAC guidelines for the following situations: 1)
treatment of CoNS from superficial wound swabs, or res-
piratory or urine specimens unless they occurred in the set-
ting of bacteremia; 2) dosing convenience defined as initial
treatment with a β-lactam antimicrobial drug during hospi-
talization with a therapeutic change to vancomycin within
24 h of discharge that was not dictated by culture results or
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agent after implantation of prosthetic materials; 4) treat-
ment of cellulitis without identification of a β-lactam-
resistant pathogen (additionally, the empiric switch to
vancomycin because of slow resolution of cellulitis was
considered noncompliant use); and 5) ongoing treatment
of infection in a patient with a history of MRSA coloniza-
tion in the absence of a diagnostic culture. If the use of
vancomycin met >1 of these specified criteria, each was
included in data collection. 
Statistical Analysis
Data were collected on a standardized form and entered
onto spreadsheets (Excel 2000, Microsoft Corporation,
Redmond, WA, USA). To evaluate predictors for compli-
ance with vancomycin use guidelines, discrete variables
were described by percentages and compared by using chi-
square or Fisher exact tests as appropriate. Continuous
variables were described by means and evaluated by using
Student t test. Variables with a p value <0.05 by univariate
analysis were evaluated by stepwise logistic regression for
inclusion in the final model. SAS version 8.2 for personal
computers (SAS Institute Inc., Cary, NC, USA) was used
for statistical analysis.
Results
During the study period, NMHHC received 323
patient referrals for continuation of parenteral van-
comycin therapy after hospitalization. The records of 27
patients (8.4%) could not be located and were not includ-
ed in the study. Thus, the final analysis included 296
patients. Table 2 summarizes the criteria that determined
whether vancomycin was prescribed within HICPAC
guidelines. One hundred eighty patients (60.8%), 5 of
whom met >1 criteria for appropriate use, received van-
comycin within guidelines. A total of 118 (65.6%) were
treated for infections caused by β-lactam-resistant, gram-
positive bacteria. Sixty-seven patients (37.2%) received
vancomycin for a reported allergic reaction to β-lactam
antimicrobial drugs. Although only the first referral for
home vancomycin was analyzed for each patient, 44
(14.9%) were referred multiple times to receive van-
comycin as outpatients (2–8 referrals per patient) during
this study.
Of the 296 patients, 116 (39.2%), 8 of whom met >1
criteria, received vancomycin outside HICPAC guidelines.
Eighty-four (72.4%) cases were for continued empiric
treatment of presumed infections in patients whose cul-
tures were negative or not obtained. This practice was
prevalent across all services. Dosing convenience led to
the use of the drug in 18 (15.5%) patients, 12 (67%) of
whom were admitted to a medical service. In 13 patients
(11.2%), home-infusion vancomycin was continued after
major surgical procedures involving implanted devices.
This practice occurred exclusively in orthopedic and neu-
rosurgery services. Finally, in 9 patients (7.8%), van-
comycin was used to treat infection with a CoNS isolate
from a single blood culture. 
Demographic and clinical characteristics are shown in
Table 3. Patients whose use of vancomycin followed
guidelines were older than those whose use did not follow
guidelines (mean age 53.6 years vs. 48.9 years, p = 0.016).
No significant differences were noted in sex or ethnicity,
although African-Americans showed a trend toward
receiving vancomycin within guidelines (p = 0.054).
Appropriate vancomycin use was more likely after a
longer mean hospital stay (12.2 days vs. 9.5 days, p =
0.007). No significant differences were noted in the mean
Charlson comorbidity score or frequency of diagnosed
coexisting medical conditions between the 2 groups with
the exception of a history of malignancy (21.7% vs.
10.3%, p = 0.012) among patients who received van-
comycin according to guidelines. Insurance status did not
differ between groups. 
Compliance with HICPAC guidelines varied according
to the inpatient prescribing service. Appropriate prescrip-
tions for vancomycin were more likely to be preceded by
discharge from a medical service (60.0% vs. 37.9%,
p<0.001). This finding was true both for discharges from
general medicine and medical subspecialty services, with
the exception of hematology/oncology. More episodes of
vancomycin infusion outside guidelines followed discharge
from a surgical service (59.5% vs. 37.2%, p<0.001), name-
ly, orthopedic and neurosurgery services (35.3% vs. 17.2%,
RESEARCH
1560 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 10, October 2005p<0.001). Inpatient consultation by an infectious diseases
specialist did not affect the appropriateness of home van-
comycin prescriptions by managing services (p = 0.641).
The infection diagnoses of patients referred for home
infusions of vancomycin are outlined in Table 4. Patients
were more likely to receive vancomycin per guidelines in
the setting of bloodstream (33.9% vs. 13.8%, p<0.001) and
urinary tract infections (20% vs. 11.2%, p = 0.042). The
microbiologic investigations undertaken and the organ-
isms identified during hospitalization are delineated in
Table 5. Appropriate use of vancomycin was more likely to
follow an attempt to make a microbiologic diagnosis
(96.1% vs. 77.6%, p<0.001). More blood, urine, and
wound cultures were obtained in this group, and the num-
ber of cultures obtained was higher when vancomycin was
used appropriately. 
Results of the multivariate analysis are shown in Table
6. Patients <65 years of age were less likely to receive
appropriate vancomycin (odds ratio [OR] 0.50, 95% confi-
dence interval [CI] 0.26–0.94). Appropriate use of van-
comycin was more likely to occur after discharge from a
medical service rather than a surgical service (OR 2.62,
95% CI 1.53–4.48). Although discharge from a hematol-
ogy/oncology service was not associated with appropriate
use of vancomycin, patients with a history of malignancy
were more likely to receive vancomycin within HICPAC
guidelines (OR 3.02, 95% CI 1.40–6.53). Obtaining a
wound culture was associated with appropriate use of van-
comycin (OR 2.08, 95% CI 1.19–3.64). Finally, patients
who underwent any microbiologic evaluation were more
likely to receive appropriate vancomycin through home
care (OR 5.93, 95% CI 2.26–15.54).
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This study examined a large group of patients referred
for home infusions of vancomycin over a 5-year period
and applied established guidelines to determine if outpa-
tient use conformed to a widely accepted benchmark. A
total of 39.2% of the prescriptions were given outside
guidelines. Several authors have applied these HICPAC
guidelines to evaluate inpatient use of vancomycin and
found the incidence of outside guidelines use to range from
36% to 79% (11,12,18,19). Our study, however, is the first
to critically evaluate the appropriateness of vancomycin in
the outpatient setting.
The most common reason for outside guidelines use of
vancomycin was continuation of empiric therapy in
patients without a culture-defining indication. Singer et al.
have found similar results in hospitalized patients (12). In
contrast, other studies found that the most common rea-
sons for inappropriate inpatient prescriptions for van-
comycin were surgical prophylaxis and failure to modify
prescriptions for antimicrobial drugs based on culture
results (19,20). 
We found that the other reasons for vancomycin use
outside guidelines were dosing convenience, prolonged
use after surgical procedures, and treatment of CoNS iso-
lated from a single blood culture. Use for dosing conven-
ience is likely underestimated (15.5%) because of the
conservative definition used in this retrospective analysis.
The incidence of vancomycin use for prolonged periods
after implantation of devices and for the treatment of
CoNS from a single blood culture was less than the inci-
dence among inpatients (12,19). This incidence may
reflect that continuing vancomycin for these indications is
more convenient in the inpatient setting and that physi-
cians are likely to reevaluate the true need for outpatient
vancomycin in these circumstances.
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physicians demonstrate that patients discharged from a
medical service are more likely to receive vancomycin
appropriately. Of surgical subspecialists, orthopedic and
neurosurgeons were more likely to prescribe vancomycin
outside guidelines. These prescribing differences are con-
sistent with the findings of inpatient vancomycin use eval-
uations (21–24). Although patients with a history of
malignancy received vancomycin according to HICPAC
guidelines, hematology/oncology was the only medical
service not associated with appropriate use. These results
suggest that the vancomycin-prescribing practices of cer-
tain subspecialists offer the opportunity for education
regarding the existence of and rationale for such guidelines
and targeted intervention to reduce unnecessary outpatient
vancomycin usage (25). Only 6 patients with end-stage
renal disease received vancomycin through homecare.
Intuitively, one might expect more vancomycin use in this
patient population; however, this finding probably reflects
that these patients receive vancomycin during hemodialy-
sis and, thus, do not require referral to home health. In con-
trast to other studies, consultation by infectious diseases
physicians did not impact compliance (26–28). This find-
ing warrants further examination to determine if infectious
diseases physicians recommend vancomycin for use out-
side of HICPAC guidelines or if their recommendations
are disregarded.
If a microbiologic evaluation was attempted, van-
comycin use was more likely to follow guidelines.
Obtaining wound cultures was also associated with appro-
priate use. A thorough microbiologic evaluation aids in
clinical decision making. When clinicians have culture and
susceptibility results, they are more likely to use van-
comycin appropriately, particularly for patients with skin
and soft tissue infections.
Patients >65 years of age were more likely to receive
vancomycin per guidelines. The reasons for this are
unclear but were not impacted by insurance status. This
finding probably reflects that patients referred for intra-
venous antimicrobial drugs through homecare either have
insurance that will reimburse for the service or have the
ability to pay for the drugs.
This study had several limitations because of its retro-
spective nature. A substantial number of patients were
classified in the compliant group on the basis of a reported
allergy to β-lactam drugs. Because we were unable to
determine the nature of reported allergies to penicillin, all
allergies were assumed to be serious in nature. Thus, this
study overestimates appropriate vancomycin use for this
purpose. Another limitation of this analysis is the inability
to account for the impact of vancomycin courses patients
may have received before this study. Finally, this study
does not address the financial consideration that influ-
enced the choice of antimicrobial drug. Other investigators
have explored this issue and found that the costs of outpa-
tient vancomycin therapy are substantial (29). The patients
in this study were preselected to the extent that they were
able to receive vancomycin at home. 
HICPAC guidelines were developed to promote judi-
cious use of vancomycin in an attempt to curtail the spread
of vancomycin-resistant enterococci and forestall the
development of S. aureus with reduced susceptibility to
glycopeptides. Although these guidelines were initially
applied to the inpatient setting, the OPAT guidelines have
recommended that they also apply to outpatients receiving
vancomycin. Apart from vancomycin, however, the OPAT
guidelines lack information regarding choices of antimi-
crobial drugs for outpatients. In addition, they do not clear-
ly prioritize conscientious use of antimicrobial drugs
above other considerations, such as cost and dosing con-
venience, when choosing outpatient therapy. These issues
need to be addressed as the emergence and spread of
antimicrobial-resistant gram-positive pathogens in the
community continue to increase. 
One in 1,000 patients in the United States is estimated
to receive outpatient infusion of antimicrobial drugs each
year (15). The trend toward increased inpatient acuity and
shorter hospital stay will undoubtedly increase this prac-
tice. Our study on first-time referrals from 1 tertiary care
hospital to its homecare agency represents only a subset of
vancomycin use in the community. The propensity for
readmissions and repeated referrals of these chronically ill
patients must be considered when analyzing the impact of
outpatient vancomycin use. In addition, vancomycin
administered by other homecare agencies, extended care
facilities, outpatient infusion centers, and outpatient dialy-
sis centers all contribute to its burgeoning use outside the
hospital. Our study indicates that further investigations
into the consequences of this practice on individual per-
sons and the community are warranted. Do the favorable
pharmacokinetics and economic attributes of vancomycin
that make it attractive for home infusion outweigh the
potential consequences of unnecessarily broad-spectrum
gram-positive coverage? Further studies are needed to
address these issues if we are to understand the dynamics
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emergence and spread of antimicrobial resistance.
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